The U.S. Food and Drug Administration (FDA) approved Trijardy XR on January 27, 2020, for the treatment of type 2 diabetes in adults.

Takeda Reveals New Data from Phase 2b Study of Mezagitamab, Showing Potential to Innovate Primary Immune Thrombocytopenia Treatment.

The U.S. Food and Drug Administration (FDA) approved Tazemetostat on January 23, 2020, for the treatment of specific types of advanced cancers, specifically epithelioid sarcoma and follicular lymphoma.

Bristol Myers Squibb's application for subcutaneous nivolumab has been validated by the European Medicines Agency.

The U.S. Food and Drug Administration (FDA) approved Teprotumumab on January 21, 2020, for the treatment of Thyroid Eye Disease (TED), also known as Graves' Eye Disease.

argenx Reveals FDA Nod for VYVGART Hytrulo in Treating Chronic Inflammatory Demyelinating Polyneuropathy.

The U.S. Food and Drug Administration (FDA) approved Avapritinib on January 9, 2020, for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

Takeda has revealed that the European Commission has given its approval for FRUZAQLA (fruquintinib) to be used as a monotherapy for adult patients suffering from metastatic colorectal cancer.

The U.S. Food and Drug Administration (FDA) approved Ubrogepant on December 23, 2019.

Bristol Myers Squibb reveals that the U.S. FDA has granted accelerated approval for KRAZATI® (adagrasib) combined with Cetuximab for adults with previously treated, advanced, or metastatic colorectal cancer (CRC) with the KRAS G12C mutation.

The U.S. Food and Drug Administration (FDA) first approved Enhertu on December 20, 2019, for the treatment of HER2-positive breast cancer.

Jun 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.